Conference Presentation of Sonnet at MedInvest Biotech and Pharmaceutical Event
Sonnet Biotechnology to Present at MedInvest Biotech & Pharma Conference
Sonnet Biotechnology Holdings, Inc., an oncology-focused biotechnology company, will present at the MedInvest Biotech & Pharma Conference on September 25, 2025, in Palo Alto, California. Raghu Rao, Interim Chief Executive Officer of Sonnet Biotechnology, will deliver the presentation at 9:40 AM PT.
Sonnet Biotechnology is a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME). Their proprietary platform, FHAB (Fully Human Albumin-Binding), is designed to specifically target tumor and lymphatic tissue.
The FHAB platform utilizes a fully human single chain antibody fragment (scFv) that binds to human serum albumin (HSA) for transport to target tissues. This platform can potentiate a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.
Sonnet's lead program, SON-1010, is a IL-12-FHAB drug in development for the treatment of solid tumors, certain types of sarcoma, and ovarian cancer. SON-1010 is being evaluated in a Phase 1/2a study in combination with Roche's atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer.
In addition to SON-1010, Sonnet is also evaluating its second program, SON-1210, an IL12-FHAB-IL15, for the treatment of pancreatic cancer.
The presentation by Sonnet Biotechnology will be available for one-on-one meetings with qualified members of the investor community who are registered to attend the conference. A live webcast of the presentation will be available on the Events page of the Investors section of the Company's website (sonnetbio.com).
The contact information for investor relations is Jenene Thomas at 908-824-0775 and [email protected]. More information about the MedInvest Biotech & Pharma Conference can be found on the conference's website.
We look forward to hearing more about Sonnet Biotechnology's promising work in the field of oncology at the MedInvest Biotech & Pharma Conference.
Read also:
- Inadequate supply of accessible housing overlooks London's disabled community
- Strange discovery in EU: Rabbits found with unusual appendages resembling tentacles on their heads
- Duration of a Travelling Blood Clot: Time Scale Explained
- Fainting versus Seizures: Overlaps, Distinctions, and Proper Responses
